ADAGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Adagene Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$2.29+0.23 (+11.17%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.53 (+30.11%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Adagene Inc. grew revenue 7332.8% to $7.67M over fiscal 2025. Free cash flow was -$15.67M.
Revenue
$7.67M
+7332.8% vs. a year earlier
Operating income
-$21.44M
FY2025
Free cash flow
-$15.67M
FY2025
EPS, diluted
-$0.30
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $7.67M
- Net income
- -$17.61M
- EPS, diluted
- -$0.30
- Free cash flow
- -$15.67M
Nine years at a glance
Fiscal years 2017 to 2025, USD
Revenue
$7.67M+7332.8% YoY
Operating income
-$21.44M
Net income
-$17.61M
EPS, diluted
-$0.30
Free cash flow
-$15.67M
Reported period